CD274 and cancer: Emerging evidence has suggested that immunotherapy, including using inhibitors to target programmed death-1 (PD-1) on effector T-cells or programmed death ligand-1 (PD-L1) on the tumor cell surface, providing adoptive cell therapy, and applying cancer vaccines, could be promising strategies to treat HCC (37, 38).